RecruitingPhase 4NCT07654413

Tamsulosin With or Without Tadalafil for Trial Without Catheter After Acute Urinary Retention Due to Benign Prostatic Hyperplasia

Tamsulosin With Versus Without Tadalafil for Trial Without Catheter After Acute Urinary Retention Due to Benign Prostatic Hyperplasia: A Prospective Double-Blind Randomized Trial

Sponsor

Beni-Suef University

Enrollment

320 participants

Start Date

Jun 8, 2026

Study Type

INTERVENTIONAL

Conditions

Acute Urinary Retention Benign Prostatic Hyperplasia Benign Prostatic Obstruction

Summary

Acute urinary retention is a common emergency in men with benign prostatic hyperplasia. After bladder drainage with a urethral catheter, patients usually undergo a trial without catheter to determine whether they can pass urine again without recatheterization. This study will evaluate whether adding tadalafil 5 mg once daily to tamsulosin 0.4 mg once daily improves the chance of successful trial without catheter in men with first-episode acute urinary retention due to presumed benign prostatic hyperplasia. Participants will be randomly assigned to receive either tamsulosin plus tadalafil or tamsulosin plus a matching placebo. Study medication will start within 24 hours after catheterization. The catheter will be removed on Day 7. If the first trial without catheter fails, the catheter will be reinserted and a second rescue trial without catheter will be performed on Day 14. The main outcome is overall catheter-free success by Day 14. Participants will also be followed for recurrent urinary retention, post-void residual urine, urinary flow, catheter-related complications, drug-related adverse events, and the need for benign prostatic hyperplasia-related surgery within 3 months.

Eligibility

Sex: MALEMin Age: 50 Years

Inclusion Criteria6

Male patient aged 50 years or older.
First episode of spontaneous painful acute urinary retention.
Successful urethral catheterization at presentation.
Drained urine volume at presentation of at least 300 mL.
Clinical impression of benign prostatic obstruction or benign prostatic hyperplasia based on history, digital rectal examination, and/or ultrasound evidence of enlarged prostate.
Ability to provide written informed consent.

Exclusion Criteria14

Previous episode of acute urinary retention.
Chronic painless urinary retention phenotype.
Active urinary tract infection or sepsis.
Gross hematuria with clot retention.
Suspected or known urethral stricture.
Neurogenic bladder or major neurologic disease affecting voiding.
History of prostate cancer or bladder cancer.
Previous prostate surgery.
Current use of nitrates or guanylate cyclase stimulators.
Contraindication to tadalafil or tamsulosin.
Severe hypotension or unstable cardiovascular disease.
Severe renal impairment.
Severe hepatic impairment.
Current or recent use of phosphodiesterase type 5 inhibitors before enrollment.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGTamsulosin

Tamsulosin 0.4 mg will be administered orally once daily as open-label background therapy in both study arms. Treatment will start within 24 hours after urethral catheterization and continue until the scheduled Day-7 trial without catheter. Participants who fail the Day-7 trial without catheter will continue treatment until the rescue trial without catheter on Day 14.

DRUGTadalafil

Tadalafil 5 mg will be administered orally once daily in the experimental arm in addition to open-label tamsulosin 0.4 mg once daily. Treatment will start within 24 hours after urethral catheterization and continue until the scheduled Day-7 trial without catheter. Participants who fail the Day-7 trial without catheter will continue treatment until the rescue trial without catheter on Day 14.

DRUGTadalafil Placebo

A matching placebo tablet will be administered orally once daily in the placebo comparator arm in addition to open-label tamsulosin 0.4 mg once daily. The placebo will be identical to tadalafil in appearance, packaging, and labeling to maintain blinding.